Spyre Therapeutics Net Income Over Time
| SYRE Stock | 36.60 0.65 1.81% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Spyre Therapeutics Performance and Spyre Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Spyre diversify its offerings? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spyre Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Spyre Therapeutics requires distinguishing between market price and book value, where the latter reflects Spyre's accounting equity. The concept of intrinsic value - what Spyre Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spyre Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spyre Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Spyre Therapeutics and related stocks such as Pharvaris BV, Immunome, and Wave Life Sciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PHVS | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (9 M) | (29.6 M) | (42.7 M) | (76.3 M) | (100.9 M) | (134.2 M) | (120.8 M) | (114.8 M) |
| IMNM | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (10.6 M) | (17.1 M) | (24.7 M) | (36.9 M) | (106.8 M) | (293 M) | (263.7 M) | (250.5 M) |
| WVE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (5.2 M) | (19.2 M) | (55.4 M) | (102 M) | (146.7 M) | (193.6 M) | (149.9 M) | (122.2 M) | (161.8 M) | (57.5 M) | (97 M) | (87.3 M) | (91.7 M) |
| NTLA | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (12.4 M) | (31.6 M) | (67.5 M) | (85.3 M) | (99.5 M) | (125.6 M) | (259.7 M) | (474.2 M) | (481.2 M) | (519 M) | (467.1 M) | (443.8 M) |
| ZYME | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (19.2 M) | (33.8 M) | (10.4 M) | (36.6 M) | (145.4 M) | (180.6 M) | (211.8 M) | 124.3 M | (118.7 M) | (122.7 M) | (110.4 M) | (115.9 M) |
| MAZE | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (114.9 M) | (100.4 M) | 52.2 M | 60.1 M | 63.1 M |
| ABCL | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | 309 K | (2.2 M) | 118.9 M | (2.2 M) | 158.5 M | (146.4 M) | (162.9 M) | (146.6 M) | (139.2 M) |
| UPB | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (23.9 M) | (20.5 M) | (62.8 M) | (56.5 M) | (59.4 M) |
| ARDX | (9.8 M) | (9.8 M) | (9.8 M) | (6.6 M) | (3.2 M) | (29.6 M) | (112.4 M) | (64.3 M) | (91.3 M) | (94.9 M) | (94.3 M) | (158.2 M) | (67.2 M) | (66.1 M) | (39.1 M) | (35.2 M) | (37 M) |
| CLDX | (1.7 M) | (44.8 M) | (59.1 M) | (81.5 M) | (118.1 M) | (127.2 M) | (128.5 M) | (93 M) | (151.2 M) | (50.9 M) | (59.8 M) | (70.5 M) | (112.3 M) | (141.4 M) | (157.9 M) | (142.1 M) | (135 M) |
Spyre Therapeutics and related stocks such as Pharvaris BV, Immunome, and Wave Life Sciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Spyre Therapeutics financial statement analysis. It represents the amount of money remaining after all of Spyre Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Spyre Therapeutics | SYRE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 221 Crescent Street, |
| Exchange | NASDAQ Exchange |
null 36.6
Check out Spyre Therapeutics Performance and Spyre Therapeutics Correlation. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Spyre Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.